刘彬 刘

Oct 2021 – Now Medchem Director Puhe biopharma Function as a leader for the discovery of novel innovation drugs, especially in oncology field. Computer-aided design (CADD) of novel target anti-tumor drugs. Participate in project initiation from the perspectives of clinical therapy, competitive products, and market. Attending the advancement of clinical projects.  Promoting the clinical trials for a novel license-in EGFRex20ins inhibitor for the treatment of NSCLC. Explaining the molecular mechanism underlying the good inhibitory activity of EGFRex20ins. Published in Eur. J. Med. Chem., as the first/corresponding author. The BTD (breakthrough therapy designation) in 1st-line treating EGFRex20ins NSCLC in China, Phase III clinical trials are ongoing.  Identify a promising best-in-class 4th-generation EGFR-TKI that possesses an optimal kinase selectivity profile, enabling it to effectively address eight prevalent EGFR mutations for the treatment of non-small cell lung cancer (NSCLC). Phase I.  Designed and biological evaluated of a novel MTA-cooperative, high BBB-penetration, PRMT5 inhibitor as synthetic-lethality therapeutics for MTAP-deleted cancers, oral presentation in 2023/2024-AACR, liscence out to Bayer. Now Phase I  WRN inhibitors as synthetic-lethality function for the treatment of MSI-H solid tumors. Now Phase I

TWO clinical programs Best in class & highly selective Rock2 inhibitors for CGVHD and IPF; phase 3 [licensed out with Graviton Bioscience in the United States for a total amount of $500 million.] BTD therapy in cGVHD. ATR inhibitors in treating advanced solid tumors, phase 1

1. Mainly focus on Medical Team construction and searching for novel anti-cancer target. 2. Trouble shooting for the synthesis of complex compounds. 3. Design novel candidates via schrodinger.